MedTrace Logo

Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma

NCT05577000 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2026-02-20

No results posted yet for this study

Summary

This is an open-label study to determine the safety of anti-B-cell maturation antigen (BCMA) Chimeric antigen receptor T-cell (CAR T) therapy in participants with Relapsed or Refractory Multiple Myeloma (RRMM).

Conditions

  • Refractory Multiple Myeloma
  • Relapsed Multiple Myeloma

Interventions

BIOLOGICAL

Manufactured Anti-BCMA CAR-T cells

Given IV

DRUG

Fludarabine

Given IV

DRUG

Cyclophosphamide

Given IV

Sponsors & Collaborators

  • Actavis Inc.

    collaborator INDUSTRY

  • University of California, Davis

    collaborator OTHER

  • Eugia Pharma Specialities Limited

    collaborator UNKNOWN

  • Thomas Martin, MD

    lead OTHER

Principal Investigators

  • Anupama Kumar, MD · University of California, San Francisco

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-18
Primary Completion
2025-11-30
Completion
2038-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05577000 on ClinicalTrials.gov